Adolescent (age group)

Lilly’s Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

1 month ago talkbio0Tagged Adolescent (age group), Body mass index procedure, Child, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, eli lilly, Hemoglobin A1c measurement, Mounjaro, SURPASS-PEDS

Mounjaro; tirzepatide; type 2 diabetes; children; adolescents; SURPASS-PEDS; A1C reduction; BMI reduction; clinical trial; Eli Lilly

Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up

8 months ago talkbio0Tagged Adolescent (age group), Approved, Bavarian Nordic, chikungunya vaccine, traveler, United States Food and Drug Administration, Vaccines, Virus-Like Particle, Vimkunya

Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers

GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

8 months ago talkbio0Tagged Adolescent (age group), Approved, Invasive meningococcal disease, Meningococcal vaccine, Penmenvy, Pfizer, SmithKline Beecham, United States Food and Drug Administration, Vaccines, Young Adult

Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults

Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study

1 year ago talkbio0Tagged Adolescent (age group), Adult, Antibodies, Bavarian Nordic, Effectiveness, mpox vaccine, MVA, MVA-BN vaccine, NIH, NIH Mouse, Response process, Safety

Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study

FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals

2 years ago talkbio0Tagged Adolescent (age group), Adults/, Approved, Condoms, Male, COVID19 (disease), Emergency Use Authorization, Half-Life Extended Monoclonal Antibody, immune compromise, Immunocompromised Host, Invivyd, Moderate (severity modifier), Pemgarda, pemivibart, Pre-Exposure Prophylaxis, Prophylactic treatment, Severe (severity modifier), United States Food and Drug Administration, VYD222

Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents